Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 3855

Summit’s disappointing survival readout raises stakes for full data

$
0
0
Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: How mature, exactly, were the data? The biotech on Friday shared new Phase 3 data for ivonescimab, its PD ...

Viewing all articles
Browse latest Browse all 3855

Trending Articles